
Shambavi Richard, MD
Internal Medicine, Cancer (Oncology), Hematology-Oncology
About Me
Shambavi Richard, MD, is Associate Professor of Medicine (Hematology and Medical Oncology) with the Center of Excellence for Multiple Myeloma. She sees multiple myeloma patients at the Ruttenberg Treatment Center at The Mount Sinai Hospital. Dr. Richard is Director of CAR T-cell Research and Stem Cell Transplant for Multiple Myeloma. In this capacity she leads innovative research in approaches for CAR T-cell treatment for multiple myeloma. Dr. Richard applies a multi-disciplinary approach for each of her patients alongside her collaborative team members.
In practice for more than 20 years, Dr. Richard has extensive experience in transplantation for multiple myeloma. She is a principal investigator and is involved in several phase 1, phase 2, and first-in-human clinical trials in multiple myeloma with a focus on novel therapies, including antibody, immunotherapy, and targeted therapy treatment approaches.
The Center of Excellence for Multiple Myeloma has played a pivotal role in the approval of several recent drugs that are now FDA approved for the treatment of multiple myeloma.
Language
Position
Hospital Affiliations
- Mount Sinai Morningside
- Mount Sinai Beth Israel
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai West
About Me
Shambavi Richard, MD, is Associate Professor of Medicine (Hematology and Medical Oncology) with the Center of Excellence for Multiple Myeloma. She sees multiple myeloma patients at the Ruttenberg Treatment Center at The Mount Sinai Hospital. Dr. Richard is Director of CAR T-cell Research and Stem Cell Transplant for Multiple Myeloma. In this capacity she leads innovative research in approaches for CAR T-cell treatment for multiple myeloma. Dr. Richard applies a multi-disciplinary approach for each of her patients alongside her collaborative team members.
In practice for more than 20 years, Dr. Richard has extensive experience in transplantation for multiple myeloma. She is a principal investigator and is involved in several phase 1, phase 2, and first-in-human clinical trials in multiple myeloma with a focus on novel therapies, including antibody, immunotherapy, and targeted therapy treatment approaches.
The Center of Excellence for Multiple Myeloma has played a pivotal role in the approval of several recent drugs that are now FDA approved for the treatment of multiple myeloma.
Language
Position
Hospital Affiliations
- Mount Sinai Morningside
- Mount Sinai Beth Israel
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai West